Search clinical trials for: FMP2.1/AS01B

Total 58 results

University of Oxford
National Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...

Completed

A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria

Plasmodium Falciparum Malaria

United Kingdom
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); The...

Completed

A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults

Malaria

United States
GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Malaria

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Herpes Zoster

United States, Spain, Czechia
University of Oxford

Completed

Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults (RTSS)

Malaria Vaccine

Thailand
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
University of Oxford
National Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...

Completed

A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

Plasmodium Falciparum Malaria

United Kingdom
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaborators

Completed

Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali

Plasmodium Falciparum Malaria

Mali
Institut Paoli-Calmettes

Completed

Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (ALLO-WT1)

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

France
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaborators

Completed

FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali

Malaria | Plasmodium Falciparum Malaria

Mali
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaborators

Completed

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

Malaria

United States
Sun Pharmaceutical Industries Limited

Completed

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Non-segmental Vitiligo

United States, India
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

Malaria

United States
GlaxoSmithKline

Completed

A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

Respiratory Syncytial Virus Infections

Japan
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

Phase I Pediatric FMP2.1/AS02A Trial in Mali

Plasmodium Falciparum Malaria

Mali
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR); The PATH Malaria...

Completed

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

Plasmodium Falciparum Malaria

United States
University of Oxford

Completed

A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S

Plasmodium Falciparum Malaria

United Kingdom
International AIDS Vaccine Initiative

Completed

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

HIV/AIDS

United States
GlaxoSmithKline

Completed

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Malaria

Ghana, Kenya
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.

Plasmodium Falciparum

Kenya
GlaxoSmithKline

Active, not recruiting

Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Hepatitis B, Chronic

Taiwan, Belgium, Thailand, Germany, Spain, Hong Kong, United Kingdom, France, Poland
GlaxoSmithKline
Walter Reed Army Institute of Research (WRAIR); The PATH Malaria Vaccine Initiative...

Completed

Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Malaria

United States
GlaxoSmithKline
PATH

Completed

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

Malaria

United States
University of Oxford

Completed

A Study to Assess the Safety and Immunogenicity of a Malaria Vaccine Candidate, R21, Administered With AS01B

Malaria

United Kingdom
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years

Clostridium Infections

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.

Respiratory Disorders

Sweden, United Kingdom
Phytopharm Consulting Brazil
Laboratório Saúde Ltda - principal e único patrocinador

Unknown

Efficacy and Safety Study for PIOLIN® Shampoo (ESPX)

PEDICULOSIS

Brazil
Dilon Medical Technologies Ltd.

Recruiting

MarginProbe 2.0 Data Collection Protocol

Breast Cancer

United States, Israel
Bill & Melinda Gates Medical Research Institute
Bill and Melinda Gates Foundation; Wellcome Trust

Recruiting

Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults

Tuberculosis

Indonesia, Kenya, South Africa, Vietnam, Malawi, Mozambique, Zambia
Bill & Melinda Gates Medical Research Institute
Wellcome Trust

Completed

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV (MESA-TB)

Human Immunodeficiency Virus

South Africa
PATH
GlaxoSmithKline; Kenya Medical Research Institute; US Army Medical Research Directorate-Africa... and other collaborators

Completed

RTS,S/AS01E Hypo-immuno-responsiveness Study

Plasmodium Falciparum

Kenya
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002)

Dengue Fever

Puerto Rico
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Influenza, Human

United States, Belgium
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

Dengue

United States
Michigan State University
Boston University; National Institute of Allergy and Infectious Diseases (NIAID) and other collaborators

Recruiting

RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi (RTSS/PBO)

Malaria, Malaria Vaccine, Insecticide-treated Bednets

Malawi
European Organisation for Research and Treatment...

Unknown

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Melanoma (Skin)

France, Spain, Belgium, Germany, Italy, United Kingdom, Netherlands
GlaxoSmithKline

Active, not recruiting

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Influenza, Human

United States
KEMRI-Wellcome Trust Collaborative Research Program
GlaxoSmithKline

Unknown

An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial (MAL059)

Malaria

Kenya
National Institute of Allergy and Infectious Diseases...

Completed

Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali

Malaria

Mali
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company

Completed

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants (HVTN 120)

HIV Infections

United States, Zimbabwe, Tanzania, Zambia
London School of Hygiene and Tropical Medicine
Malaria Research and Training Center, Bamako, Mali; Institut de Recherche en...

Completed

Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) (RTSS-SMC)

Children, Only | Malaria,Falciparum

Burkina Faso, Mali
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Influenza, Human

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaborators

Completed

Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine

Malaria, Falciparum

Kenya
London School of Hygiene and Tropical Medicine
Malaria Research and Training Center, Bamako, Mali; Institut de Recherche en...

Completed

Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (RTSS-SMC)

Child, Only | Malaria,Falciparum

Mali, Burkina Faso
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaborators

Completed

Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali

Malaria

Mali
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Malaria | Malaria Vaccines

Ghana
GlaxoSmithKline

Completed

Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.

Malaria

Kenya, Tanzania

Search clinical trials for: FMP2.1/AS01B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations